These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
312 related articles for article (PubMed ID: 19622627)
1. Bone mineral density and effects of growth hormone treatment in prepubertal children with Prader-Willi syndrome: a randomized controlled trial. de Lind van Wijngaarden RF; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; van Leeuwen M; Haring DA; Bocca G; Mieke Houdijk EC; Hokken-Koelega AC J Clin Endocrinol Metab; 2009 Oct; 94(10):3763-71. PubMed ID: 19622627 [TBL] [Abstract][Full Text] [Related]
2. Bone mineral density in children and adolescents with Prader-Willi syndrome: a longitudinal study during puberty and 9 years of growth hormone treatment. Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Van Alfen AA; Van Leeuwen M; Van Wieringen H; Wegdam-den Boer ME; Zwaveling-Soonawala N; Hokken-Koelega AC J Clin Endocrinol Metab; 2015 Apr; 100(4):1609-18. PubMed ID: 25668198 [TBL] [Abstract][Full Text] [Related]
3. Two years of growth hormone treatment in adults with Prader-Willi syndrome do not improve the low BMD. Jørgensen AP; Ueland T; Sode-Carlsen R; Schreiner T; Rabben KF; Farholt S; Høybye C; Christiansen JS; Bollerslev J J Clin Endocrinol Metab; 2013 Apr; 98(4):E753-60. PubMed ID: 23436915 [TBL] [Abstract][Full Text] [Related]
4. Bone mineral density and body composition in short children born SGA during growth hormone and gonadotropin releasing hormone analog treatment. Lem AJ; van der Kaay DC; Hokken-Koelega AC J Clin Endocrinol Metab; 2013 Jan; 98(1):77-86. PubMed ID: 23125290 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of long-term continuous growth hormone treatment in children with Prader-Willi syndrome. de Lind van Wijngaarden RF; Siemensma EP; Festen DA; Otten BJ; van Mil EG; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Bocca G; Houdijk EC; Hoorweg-Nijman JJ; Vreuls RC; Jira PE; van Trotsenburg AS; Bakker B; Schroor EJ; Pilon JW; Wit JM; Drop SL; Hokken-Koelega AC J Clin Endocrinol Metab; 2009 Nov; 94(11):4205-15. PubMed ID: 19837938 [TBL] [Abstract][Full Text] [Related]
6. Bone mineral density in young adults with Prader-Willi syndrome: A randomized, placebo-controlled, crossover GH trial. Donze SH; Kuppens RJ; Bakker NE; van Alfen-van der Velden JAEM; Hokken-Koelega ACS Clin Endocrinol (Oxf); 2018 Jun; 88(6):806-812. PubMed ID: 29418016 [TBL] [Abstract][Full Text] [Related]
7. Randomized controlled GH trial: effects on anthropometry, body composition and body proportions in a large group of children with Prader-Willi syndrome. Festen DA; de Lind van Wijngaarden R; van Eekelen M; Otten BJ; Wit JM; Duivenvoorden HJ; Hokken-Koelega AC Clin Endocrinol (Oxf); 2008 Sep; 69(3):443-51. PubMed ID: 18363884 [TBL] [Abstract][Full Text] [Related]
8. Changes in bone mineral density, body composition, and lipid metabolism during growth hormone (GH) treatment in children with GH deficiency. Boot AM; Engels MA; Boerma GJ; Krenning EP; De Muinck Keizer-Schrama SM J Clin Endocrinol Metab; 1997 Aug; 82(8):2423-8. PubMed ID: 9253311 [TBL] [Abstract][Full Text] [Related]
9. Long-term effects of growth hormone (GH) treatment on body composition and bone mineral density in short children born small-for-gestational-age: six-year follow-up of a randomized controlled GH trial. Willemsen RH; Arends NJ; Bakker-van Waarde WM; Jansen M; van Mil EG; Mulder J; Odink RJ; Reeser M; Rongen-Westerlaken C; Stokvis-Brantsma WH; Waelkens JJ; Hokken-Koelega AC Clin Endocrinol (Oxf); 2007 Oct; 67(4):485-92. PubMed ID: 17561977 [TBL] [Abstract][Full Text] [Related]
10. Randomized controlled trial to investigate the effects of growth hormone treatment on scoliosis in children with Prader-Willi syndrome. de Lind van Wijngaarden RF; de Klerk LW; Festen DA; Duivenvoorden HJ; Otten BJ; Hokken-Koelega AC J Clin Endocrinol Metab; 2009 Apr; 94(4):1274-80. PubMed ID: 19158197 [TBL] [Abstract][Full Text] [Related]
11. Eight years of growth hormone treatment in children with Prader-Willi syndrome: maintaining the positive effects. Bakker NE; Kuppens RJ; Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Bindels-de Heus GC; Bocca G; Haring DA; Hoorweg-Nijman JJ; Houdijk EC; Jira PE; Lunshof L; Odink RJ; Oostdijk W; Rotteveel J; Schroor EJ; Van Alfen AA; Van Leeuwen M; Van Pinxteren-Nagler E; Van Wieringen H; Vreuls RC; Zwaveling-Soonawala N; de Ridder MA; Hokken-Koelega AC J Clin Endocrinol Metab; 2013 Oct; 98(10):4013-22. PubMed ID: 24001750 [TBL] [Abstract][Full Text] [Related]
12. Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency. Högler W; Briody J; Moore B; Lu PW; Cowell CT Bone; 2005 Nov; 37(5):642-50. PubMed ID: 16139578 [TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and metabolic risk profile and acylation-stimulating protein levels in children with Prader-Willi syndrome and effects of growth hormone treatment. de Lind van Wijngaarden RF; Cianflone K; Gao Y; Leunissen RW; Hokken-Koelega AC J Clin Endocrinol Metab; 2010 Apr; 95(4):1758-66. PubMed ID: 20173020 [TBL] [Abstract][Full Text] [Related]
14. Bone mineral density and body composition before and during treatment with gonadotropin-releasing hormone agonist in children with central precocious and early puberty. Boot AM; De Muinck Keizer-Schrama S; Pols HA; Krenning EP; Drop SL J Clin Endocrinol Metab; 1998 Feb; 83(2):370-3. PubMed ID: 9467543 [TBL] [Abstract][Full Text] [Related]
15. Sustained benefit after 2 years of growth hormone on body composition, fat utilization, physical strength and agility, and growth in Prader-Willi syndrome. Myers SE; Carrel AL; Whitman BY; Allen DB J Pediatr; 2000 Jul; 137(1):42-9. PubMed ID: 10891820 [TBL] [Abstract][Full Text] [Related]
16. The effect of growth hormone treatment on bone mineral density in prepubertal girls with Turner syndrome: a multicentre prospective clinical trial. Aycan Z; Cetinkaya E; Darendeliler F; Vidinlisan S; Bas F; Bideci A; Demirel F; Darcan S; Buyukgebiz A; Yildiz M; Berberoglu M; Bundak R Clin Endocrinol (Oxf); 2008 May; 68(5):769-72. PubMed ID: 17980015 [TBL] [Abstract][Full Text] [Related]
17. Elevated insulin-like growth factor-I values in children with Prader-Willi syndrome compared with growth hormone (GH) deficiency children over two years of GH treatment. Feigerlová E; Diene G; Oliver I; Gennero I; Salles JP; Arnaud C; Tauber M J Clin Endocrinol Metab; 2010 Oct; 95(10):4600-8. PubMed ID: 20926543 [TBL] [Abstract][Full Text] [Related]
18. Beneficial effects of growth hormone treatment on cognition in children with Prader-Willi syndrome: a randomized controlled trial and longitudinal study. Siemensma EP; Tummers-de Lind van Wijngaarden RF; Festen DA; Troeman ZC; van Alfen-van der Velden AA; Otten BJ; Rotteveel J; Odink RJ; Bindels-de Heus GC; van Leeuwen M; Haring DA; Oostdijk W; Bocca G; Mieke Houdijk EC; van Trotsenburg AS; Hoorweg-Nijman JJ; van Wieringen H; Vreuls RC; Jira PE; Schroor EJ; van Pinxteren-Nagler E; Willem Pilon J; Lunshof LB; Hokken-Koelega AC J Clin Endocrinol Metab; 2012 Jul; 97(7):2307-14. PubMed ID: 22508707 [TBL] [Abstract][Full Text] [Related]
19. Dietary Energy Intake, Body Composition and Resting Energy Expenditure in Prepubertal Children with Prader-Willi Syndrome before and during Growth Hormone Treatment: A Randomized Controlled Trial. Bakker NE; Siemensma EP; Koopman C; Hokken-Koelega AC Horm Res Paediatr; 2015; 83(5):321-31. PubMed ID: 25764996 [TBL] [Abstract][Full Text] [Related]
20. Effects of 8 years of growth hormone treatment on scoliosis in children with Prader-Willi syndrome. Grootjen LN; Rutges JPHJ; Damen L; Donze SH; Juriaans AF; Kerkhof GF; Hokken-Koelega ACS Eur J Endocrinol; 2021 May; 185(1):47-55. PubMed ID: 33886496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]